help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Maki, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maki, R.
The Oncologist, Vol. 6, No. 4, 333-337, August 2001
© 2001 AlphaMed Press

ASCO 2001: CRITICAL COMMENTARIES PART 1

Sarcoma

Robert Maki

Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Correspondence: Robert Maki, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center, Sarcoma Program, Box 223, 1275 York Avenue, New York, New York 10021-6007, USA. Telephone: 212-639-5720; Fax: 212-717-3394; e-mail: makir{at}mskcc.org

ASCO 2001 was a banner year for innovative systemic therapy for sarcomas. Imatinib mesylate (STI571, GleevecTM) shows clear activity not only in chronic myelogenous leukemia, for which the drug received Food and Drug Administration approval, but also in gastrointestinal stromal tumors as well, by virtue of imatinib mesylate binding to the abl, kit, and platelet-derived growthfactor receptor tyrosine kinases. Ecteinascidin-743 (ET-743) demonstrates activity against a fraction of other soft-tissue sarcomas. Gemcitabine-based regimens show at least some activity against a subset of soft-tissue sarcomas. Given the lack of new agents for sarcoma therapy since the development of ifosfamide, these studies give hope that the term "effective systemic therapy for sarcoma" might become a reality.

Key Words. Sarcoma • Treatment • ASCO




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
N. K. Pryer, L. B. Lee, R. Zadovaskaya, X. Yu, J. Sukbuntherng, J. M. Cherrington, and C. A. London
Proof of Target for SU11654: Inhibition of KIT Phosphorylation in Canine Mast Cell Tumors
Clin. Cancer Res., November 15, 2003; 9(15): 5729 - 5734.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. A. London, A. L. Hannah, R. Zadovoskaya, M. B. Chien, C. Kollias-Baker, M. Rosenberg, S. Downing, G. Post, J. Boucher, N. Shenoy, et al.
Phase I Dose-Escalating Study of SU11654, a Small Molecule Receptor Tyrosine Kinase Inhibitor, in Dogs with Spontaneous Malignancies
Clin. Cancer Res., July 1, 2003; 9(7): 2755 - 2768.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Scotlandi, S. Perdichizzi, M. C. Manara, M. Serra, S. Benini, V. Cerisano, R. Strammiello, M. Mercuri, G. Reverter-Branchat, G. Faircloth, et al.
Effectiveness of Ecteinascidin-743 against Drug-sensitive and -resistant Bone Tumor Cells
Clin. Cancer Res., December 1, 2002; 8(12): 3893 - 3903.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. T. Liao, M. B. Chien, N. Shenoy, D. B. Mendel, G. McMahon, J. M. Cherrington, and C. A. London
Inhibition of constitutively active forms of mutant kit by multitargeted indolinone tyrosine kinase inhibitors
Blood, June 28, 2002; 100(2): 585 - 593.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2001 by AlphaMed Press.